MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)Business Wire • 09/12/23
MindMed Reports Second Quarter 2023 Financial Results and Business HighlightsBusiness Wire • 08/03/23
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120Business Wire • 08/03/23
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 07/31/23
Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming resultsProactive Investors • 06/27/23
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceBusiness Wire • 06/22/23
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.Market Watch • 06/21/23
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor DayBusiness Wire • 06/20/23
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th DeadlineBusiness Wire • 06/09/23
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company NomineesBusiness Wire • 06/08/23
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company NomineesBusiness Wire • 06/05/23
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120PRNewsWire • 06/05/23
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and ShareholdersBusiness Wire • 05/25/23
MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development StrategyBusiness Wire • 05/25/23
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual MeetingBusiness Wire • 05/24/23